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SUMMARY
Background
Many patients with cardiovascular (CV) disease will stop aspirin (ASA)
because of ASA-related dyspepsia. Proton pump inhibitor (PPI) co-therapy
may reduce ASA-related dyspepsia, enhancing ASA adherence and improv-
ing CV outcomes.
Aim
To explore the impact of PPI co-therapy on CV outcomes in long-term,
low-dose ASA users.
Methods
We modified a previously published Markov model to assess the long-term
impact of PPI co-therapy on CV and upper gastrointestinal bleeding
(UGIB) outcomes among patients using ASA for secondary CV prevention.
UGIB events, recurrent myocardial infarctions (MIs) and incremental cost-
effectiveness ratios (ICERs) were measured. The perspective taken was that
of a long-term payer.
Results
Compared with ASA alone, ASA plus PPI resulted in fewer lifetime UGIB
events (3.4% vs. 7.2%) and increased ASA adherence (74% vs. 71%). Increased
ASA adherence resulted in fewer recurrent MIs (26 fewer events per 10 000
patients). On average, the ASA plus PPI strategy resulted in 38 additional days
of life per patient, with the majority of this benefit (61%) because of a reduc-
tion in CV mortality (rather than UGIB-related mortality). ASA plus PPI was
also more costly than ASA alone, with an ICER of $19 000 per life-year saved.
Results were sensitive to cost of PPI and impact of PPI on ASA adherence.
Conclusions
Proton pump inhibitor co-therapy has the potential to impact not only GI,
but also CV outcomes in patients with CV disease using ASA and such
co-therapy is likely to be cost-effective. Future studies should better quan-
tify the CV benefits of PPI co-therapy.
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INTRODUCTION
Guidelines recommend that patients with cardiovascular
(CV) disease use low-dose aspirin (ASA) for secondary
CV prevention.1 However, up to 30% of patients will not
consistently take their medication,2–4 placing them at
increased risk for recurrent CV events.5, 6 In a recent
trial of patients with established CV disease presenting
with peptic ulcer bleeding, mortality was increased in
patients in whom ASA was withheld, emphasising the
hazard of even short-term ASA discontinuation.7 Strate-
gies to improve ASA adherence can therefore improve
CV outcomes.
Several studies have suggested that ASA-related dys-
pepsia is an important reason for ASA discontinuation.
In the British Doctors’ Trial, 20% of participants dis-
continued ASA within 1 year, and half of these patients
cited dyspepsia as the reason for discontinuation.8 In
the CAPRIE study, 40% of patients who discontinued
ASA did so because of dyspepsia.9 Similarly, another
study reported that 50% of patients who stopped ASA
did so because of side effects, with GI side effects being
most common.10 Unfortunately, most patients who dis-
continue ASA do so without consulting their physi-
cian.11 Therefore, preemptive efforts to reduce dyspepsia
are likely to be more effective than symptom-driven
efforts. One preemptive strategy for reducing dyspepsia
is proton pump inhibitor (PPI) co-therapy. PPIs have
been widely studied for reducing NSAID-related
dyspepsia.12 However, studies of PPI co-therapy on
ASA-related dyspepsia are lacking. One approach to
determining whether studies on this topic are worth-
while is to use modelling techniques to define the
potential effects of PPI co-therapy on ASA adherence
and CV outcomes.
The purpose of this study was to model the effects of
PPI co-therapy in patients taking low-dose ASA for sec-
ondary prevention. We modified a recently published
Markov model,13 modelling dyspepsia as a modifiable
cause of ASA discontinuation. Prior work and has dem-
onstrated that PPI co-therapy may be cost-effective
because of a reduction in upper GI bleeding events;13, 14
the aim of this study was to explicitly examine the
potential reduction in CV events with PPI co-therapy.
METHODS
We modified an existing Markov model of ASA and PPI
use (Figure 1).13 Two competing strategies were mod-
elled: (i) ASA alone strategy, where the cohort began on
ASA alone and PPI was added if upper GI bleeding
occurred; and (ii) ASA plus PPI strategy, in which the
entire cohort began on ASA plus PPI. The cohort was
comprised of 50 year-old patients with no risk factors
for upper GI bleeding, using ASA for secondary preven-
tion. Our previous work, which modelled only the GI
benefits of PPIs, suggested that PPI co-therapy was cost-
effective in older (age >65) but not younger patients.13
For the current study, which modelled not only GI but
also CV benefits, we selected a younger population for
the base-case, anticipating that the cost-effectiveness of








adherence ASA + PPIASA ± PPI
Clopidogrel
± PPI
Figure 1 | Markov Model Structure. All patients begin the simulation in an ASA alone state or ASA plus PPI state
(ASA  PPI) (depending on the strategy being modelled). The non-adherence state can be entered due to ASA-related
dyspepsia or for reasons unrelated to dyspepsia (see text). A CV event or GI bleed is an event that can occur within
any state. A non-CV ⁄non-GI death state can be reached from any state (not shown). The clopidogrel state is a
temporary (1-year) state that ultimately returns to an ASA  PPI state or transitions to a death state.
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taken into account. Age was varied widely in sensitivity
analysis. The simulation began with the cohort in an
ASA state  PPI (depending on the strategy). The
cohort could remain in the ASA state or transition to a
non-adherence state [no ASA or PPI until GI bleeding
or recurrent myocardial infarction (MI) occurred]. Dur-
ing any state, a patient could experience an upper GI
bleeding event or a recurrent MI. GI bleeding resulted in
transition to a high-risk state for future upper GI bleed-
ing or to a death state.15, 16 Recurrent MI resulted in: (i)
hospitalisation followed by return to the current state;
(ii) hospitalisation followed by transition to an
ASA + clopidogrel state for 1 year (with PPI co-therapy
only in patients at high-risk for GI bleeding); or (iii)
transition to a death state.
Gastrointestinal effects
Risk of upper gastrointestinal bleeding. The risk of
upper GI bleeding in low-dose ASA users was estimated
from published literature (Table 1). We performed a
MEDLINE search for English-language systematic
reviews of ASA and GI bleeding published since the year
Table 1 | Base-case assumptions of variables in model and ranges tested in sensitivity analysis
Description Base-case Sensitivity analysis range References
Costs
Acute UGIB $7757* $3878 to $15 514 (G) 38
Myocardial infarction $10 305* $5152 to $20 610 (G) 38
Aspirin (ASA) $2 $1 to $4 (G) 39
Clopidogrel $1539 $769 to $3078 (G) 39
Generic PPI $144 $72 to $288 (G) 39
Branded PPI $1515 $757 to $3030 39
Probabilities and risks
for CV events
CV event (without ASA) 8% 6% to 10% (B) 28
RR of CV event with ASA 0.81 0.75 to 0.87 (N) 28
Death from CV event 50% 25% to 75% (B) 28
Clopidogrel · 1 year after CV event 50% 25% to 75% (B) 57
ASA discontinuation (year 1) 20% 5% to 30% (B) 2–4, 11, 30–33
Probabilities and risks for GI events
UGIB (on ASA) Age-dependent
(0.5% at age 65)
Average to 8-fold increased 18, 21
RR of bleed on PPI 0.33 0.18 to 0.60 (N) 15, 24, 25, 58
Death following UGIB Age-dependent
(10% at age 65)
0.5 to 2.0 of base-case (N) 22, 23
RR of recurrent UGIB 4.0 2.0 to 8.0 (N) 15, 16
Other
Absolute increase in ASA
adherence with PPI
2.5% 0% to 5% (B) 8, 10, 12, 30, 36
Discount rate 3% 0% to 10% (B) Assumed
Starting age of cohort 50 years 25 to 80 years Assumed
UGIB, upper gastrointestinal bleeding; CV, cardiovascular; RR, relative risk; PPI, proton pump inhibitor; PCI, percutaneous coronary
intervention (stent); G, gamma distribution, B, beta distribution and N, normal distribution (indicating distributions utilised for
selected variables in probabilistic sensitivity analysis).
* Costs for UGIB and myocardial infarction are weighted averages of DRG codes for Medicare admissions (see text).
 Costs for medications are per year.
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2000. We identified four reviews from which we
extracted summary relative risks and crude annual risks
of upper GI bleeding in low-dose ASA users (0.25% at
age 50, 0.5% at age 65 and 1% at age 80).17–20
Commonly accepted risk factors for upper GI bleeding
in patients taking low-dose ASA include age, prior his-
tory of upper GI bleeding and concomitant NSAID
use.21 Age-related risk is unique in that it is dynamic,
increasing gradually over the lifetime. We therefore mod-
elled age-related risk separately from other ‘static’ risk
factors.22 Furthermore, we assumed that age-related risk
could be multiplicatively combined with these other risk
factors. The risk of death following upper GI bleeding
was also age-dependent (10% at age 65).23, 24
Effectiveness of proton pump inhibitor co-therapy: upper
gastrointestinal bleeding. The effectiveness of PPI co-
therapy in reducing upper GI bleeding risk was estimated
from published literature (Table 1). We performed a
MEDLINE search for English-language studies of ASA,
PPIs and GI bleeding published since the year 1980,
identifying two randomised controlled trials of PPI co-
therapy in low-dose ASA users, both of which enrolled
only patients at high risk for upper GI bleeding and
reported a reduction in upper GI bleeding risk of over
90%.25, 26 Data in average-risk patients was more limited
and was observational, with studies reporting a risk
reduction of 60–70%.15, 17, 27 Based on the totality of
these data, we conservatively assumed that PPIs reduced
bleeding risk by 66% in our base-case analysis and varied
this effect widely in sensitivity analysis. A similar reduc-
tion in upper GI bleeding risk was assumed for patients
using clopidogrel.27, 28
Effectiveness of proton pump inhibitor co-therapy: dys-
pepsia. The impact of PPI therapy on dyspepsia was
obtained from studies of PPI co-therapy in non-ASA
NSAID users. Specifically, we utilised data from a
systematic review on this topic that reported a risk
reduction of 66%,12 conservatively assuming that PPI
co-therapy eliminated ASA-related dyspepsia in 50% of
patients.
Cardiovascular effects
Cardiovascular risk. The risk of recurrent MI was
obtained from a recent meta-analysis.29 Specifically, we
assumed that the probability of a recurrent MI without
ASA was 8% per year. Based on Framingham data, we
assumed that this risk was independent of age.30 We
assumed that ASA reduced the risk of recurrent events
by 19%.29 We also assumed that 50% of recurrent MIs
were fatal.29
Aspirin adherence. The probability of ASA discontinua-
tion was obtained from the published literature on this
topic. Specifically, we identified both short-term
(£1 year)2–4, 8, 11, 31–34 and long-term (5–10 year)8, 31, 35–38
studies that reported the rate of ASA use in patients who
had been prescribed this medication for CV prevention.
These studies report that approximately 20% of patients
prescribed ASA after a CV event will have discontinued
ASA at 1 year and that 25% to 40% of patients will have
discontinued ASA by 5 years. We therefore modelled a
nonlinear adherence curve as suggested by these data,
assuming that the probability of ASA discontinuation
was 20% at the end of year 1, with the probability of dis-
continuation dropping exponentially (i.e. becoming
incrementally less likely) in each subsequent year. This
approach yielded an adherence rate of 66% at 5 years.
Impact of proton pump inhibitor co-therapy on aspirin
adherence
Aspirin adherence was modelled in a binary fashion (i.e.,
we assumed that patients were using ASA or not using
ASA within a given year). We assumed that 20% of the
cohort stopped ASA during the first year. Based on avail-
able data, we conservatively estimated that the majority
of these patients (75%) discontinued ASA for reasons
other than dyspepsia (i.e., not modifiable by PPI co-ther-
apy).8, 10 Assuming that 50% of dyspeptic patients would
respond to PPI co-therapy and remain on ASA, we cal-
culated a discontinuation probability of 17.5% during
year 1 of the ASA plus PPI strategy (compared to 20%
under the ASA alone strategy) (0.2–0.2 · 0.25
· 0.5 = 0.175). Thus, PPI co-therapy increased the pro-
portion of patients using ASA in year 1 by 2.5% (i.e.
ASA was used by 25 additional patients per 1000 in the
ASA + PPI arm). We varied this PPI-mediated increase
in ASA adherence between 0% and 5%.
Cost inputs
Costs of upper GI bleeding and MI were obtained from
2007 Healthcare Cost and Utilization Project (HCUP)
Nationwide Inpatient Sample Medicare data (simple
weighted averages of DRG categories 174–175 and 121–
123 respectively) (Table 1).39 We used average costs for
MI rather than unique costs for various acute coronary
syndromes (ACS). Medication costs were obtained from
the 2009 Thomson Red Book.40 All costs were varied
between half and twice the base-case value in sensitivity
S. D. Saini et al.
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analysis, discounted at 3% per year and adjusted for
inflation to 2009 U.S. dollars.
Outcomes
Clinical outcomes included: (i) upper GI bleeding events
and mortality; (ii) recurrent MIs and associated mortal-
ity; (iii) ASA adherence; and (iv) life years. We also cal-
culated the proportion of PPI benefit that was attributed
to reduced CV vs. GI mortality. Economic outcomes
included costs and incremental cost-effectiveness ratios
(ICERs). Quality-adjusted life-years (QALYs) were not
measured (biasing results in favour of the ASA alone
arm by overestimating quality of life after recurrent MI).
Sensitivity analysis
One-way sensitivity analysis was performed on each vari-
able in the model. Multivariate sensitivity analysis was
performed on variables found to be important in one-
way analysis. Probabilistic sensitivity analysis was also
performed where 15 variables were simultaneously varied
over their sensitivity analysis ranges according to speci-
fied probability distributions (10 000 Monte Carlo tri-
als).41 Beta and gamma distributions were assumed for
proportions and costs respectively. Normal distributions
were assumed for log relative risks. For each distribution,
we assumed that the mean was equal to the point esti-
mate and that the standard deviation was equal to the
sensitivity analysis range ⁄ [2 · 1.96].
RESULTS
Base-case analysis
The ASA plus PPI strategy resulted in fewer lifetime
upper GI bleeding events than ASA alone (3.4% vs. 7.2%
lifetime risk) and fewer upper GI bleeding-related deaths
than ASA alone (0.4% vs. 0.8%), with relative risk reduc-
tions (RRRs) of 53% and 53% respectively (Table 2). As
a result of this impact on bleeding, PPI co-therapy
resulted in 14 additional days of life per patient.
The ASA plus PPI strategy also resulted in enhanced
ASA adherence, with the ASA plus PPI cohort using
ASA an average of 245 days longer than the ASA alone
cohort (4771 vs. 4526 days). The ASA plus PPI cohort
spent 74% of the simulation using ASA (4771 ⁄
6476 days), whereas the ASA alone cohort spent 71%
using ASA (4543 ⁄ 6438 days). This improvement in ASA
adherence resulted in a slight reduction in lifetime CV
events and deaths (26 and 13 deaths avoided per 10 000
patients respectively). As a result of this improvement in
adherence, PPI co-therapy resulted in 23 additional days
of life related to reduced CV mortality. Overall, PPI
co-therapy resulted in 38 additional days of life (14
because of reduced upper GI bleeding-related mortality
and 23 because of reduced CV mortality) at an added
lifetime cost of approximately $1,000 per patient, result-
ing in an incremental cost-effectiveness ratio (ICER) of
$19 000 per life-year saved (LYS). Notably, nearly two-
thirds of the observed benefit of PPI co-therapy in the
base-case (23 ⁄ 38 days of life gained) were attributed to a
reduction in CV (rather than GI bleeding-related) mor-
tality.
Sensitivity analysis
Results were sensitive to two variables: (i) the cost of PPI
(base: $144 per year, range: $72 to $3030); and (ii) the
absolute increase in ASA adherence with PPI co-therapy
(base: 2.5%, range: 0% to 5%). As PPI cost decreased, the
ICER of the ASA plus PPI strategy also decreased, with
PPI co-therapy becoming cost-neutral (equivalent in cost
to the ASA alone strategy) at a PPI cost of $25 per year
(Figure 2). At branded PPI cost, PPI co-therapy was only
cost-effective in patients at increased risk for GI bleeding
(Figure 2). Increased ASA adherence due to PPI co-ther-
apy also had strong effects on the ICER of the ASA plus
PPI strategy (Figure 3). Specifically, improving ASA
adherence by as little as 0.2% (2 additional patients using
ASA per 1000) reduced the ICER of the ASA plus PPI
strategy below $50 000 per LYS. With only 1% improve-
ment in ASA adherence, approximately one-third of the
benefit of PPI co-therapy was attributed to reduced CV
mortality and this proportion increased with further
improvements in ASA adherence (Figure 4). Notably,
these results were independent of the underlying proba-
bility of ASA discontinuation. Probabilistic sensitivity
analysis confirmed our results, with a median ICER of
$19 180 per LYS ($11 683 to $31 991) and 87% of
Monte Carlo trials costing less than $50 000 per LYS.
The ASA plus PPI strategy remained cost-effective
regardless of the starting age of the cohort.
Table 2 | Life-years, costs ($) and incremental cost-
effectiveness ratios (ICERs) of ASA alone and
ASA + PPI strategies (discounted at 3% per year)
Strategy Cost ($) Life-years ICER ($)
ASA alone $10 010 12.4534 –
ASA + PPI $11 059 12.5086 $19 001
Cardiovascular benefits of proton pump inhibitor co-therapy
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DISCUSSION
Summary of key findings
Low-dose ASA is recommended in patients with CHD to
decrease recurrent CV events.1 Unfortunately, a substan-
tial minority of patients discontinue ASA without con-
sulting a physician.2–4, 11 One important reason for non-
adherence is dyspepsia, an adverse effect that could be
mitigated by PPI co-therapy.8–10, 12 Our study suggests
that PPI co-therapy could reduce both GI and CV events
in patients with CHD, making it cost-effective at generic
PPI cost. Notably, clinically important improvements in
CV outcomes are seen even with small increases in ASA
adherence.
Literature review
Cessation of ASA has been shown to increase the risk of
recurrent CV events in multiple studies. Collet and col-
leagues followed 1358 patients status-post recent MI.42
These authors found that the short-term risk of a recur-
rent CV event was doubled (OR = 2.05) in patients who
stopped ASA. Similarly, Ferrari and colleagues studied
1236 patients admitted with ACS.43 These authors also
found that the risk of a recurrent CV event increased
two-fold in patients who stopped ASA, and such patients
tended to have more severe disease on presentation. In
another prospective study, authors found that ASA non-
adherence had not only short-term, but also long-term
implications, with non-adherent patients again having
nearly twice the risk of a recurrent CV event compared
with adherent patients.2 Most recently, Sung et al.
reported that the risk of recurrent CV events was mark-
edly increased in patients with peptic ulcer bleeding in
whom ASA was temporarily withheld.7
If long-term ASA adherence (ASA persistence) is sub-
optimal, how can ASA persistence be enhanced?
Although several studies have investigated interventions
to improve prescription of ASA at the time of hospital
discharge after an acute CV event,44–46 the literature on
improving persistence is more sparse. Theories of
behavioural change and chronic disease management
suggest that the optimal approach is likely to be multi-
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Figure 2 | Sensitivity analysis on PPI cost and risk of
upper GI bleeding. Solid black line indicates ICERs for
patients at average risk for UGIB (base-case assump-
tion), dashed line = 4X increased risk and dotted
line = 8X increased risk.
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Figure 3 | Sensitivity analysis on absolute increase in
proportion of patients using aspirin. Dashed vertical line
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Figure 4 | Days of life gained due to PPI-mediated
reduction in gastrointestinal and cardiovascular events.
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issue of ASA intolerance. Furthermore, the CV events
related to ASA non-adherence often occur within mere
weeks of drug cessation.5 The use of PPI co-therapy cir-
cumvents these issues, albeit at increased cost. However,
our study suggests that the benefits of co-therapy are
likely to be worth this added cost, with an ICER of
$19 000 per LYS.
Strengths and limitations
Several important limitations of our study should be
highlighted. First, as a modelling exercise, our study is
limited by the logic and assumptions of the model. How-
ever, assumptions were tested in multiple sensitivity anal-
yses and we were conservative with our base-case
estimates (e.g. RR of upper GI bleeding with PPI co-
therapy) and our model structure (e.g. assuming that CV
events did not reduce quality of life in the ASA alone
arm). We also did not model CV events other than MI,
essentially assuming that ASA had no effect on stroke
and other forms of vascular disease. As a result, however,
our findings are likely to underestimate the benefit of
PPI co-therapy on CV outcomes. Second, data on ASA-
related dyspepsia and the effectiveness of PPI co-therapy
in reducing dyspepsia are limited. To address this point,
we explored the importance of these variables in sensitiv-
ity analysis. Finally, we assumed no long-term adverse
effects from PPI therapy. Recent observational studies
have raised concerns about an increased risk of commu-
nity-acquired pneumonia and hip fractures in patients
on long-term PPI therapy.47–52 Clostridium difficile and
other enteric infections have also been reported.53–55
However, many of these associations are linked to high-
dose PPI therapy (which is not necessary for reduction
of ASA-related adverse effects). We also did not model
the potential interaction between PPIs and clopidogrel.56
However, we assumed that patients using clopidogrel
would only receive PPI if they were at increased risk for
bleeding, an assumption supported by a recent joint
consensus statement.57 The safety of long-term PPI
therapy may ultimately have important implications for
the cost-effectiveness of PPI-based gastroprotective
strategies.
Several important strengths of our study should also
be mentioned. First, we utilised a continuous, age-depen-
dent risk of upper GI bleeding. Prior studies have used a
static or step-wise risk, which may overestimate the ben-
efit of PPI co-therapy in younger patients and underesti-
mate the benefit in older patients. Most importantly, we
also explored the impact of PPI co-therapy on CV events
rather than simply GI events, which have been the focus
of prior studies.
CONCLUSIONS
In summary, PPI co-therapy is cost-effective by tradi-
tional standards in patients taking long-term, low-dose
ASA for secondary prevention provided that the PPI is
available at generic prices. Notably, PPI co-therapy has
the potential to improve not only GI but also CV out-
comes. Future studies of PPI co-therapy should better
quantify the CV benefits of these medications.
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